胸腺球蛋白
免疫抑制
医学
移植
外科
肾移植
淋巴细胞
内科学
作者
Irfan Agha,Jose Rueda,A. Alvarez,Gary G. Singer,Brent W. Miller,Karen Flavin,Jeffrey A. Lowell,Surendra Shenoy,Todd K. Howard,Venkataraman Ramachandran,William Irish,Mark A. Schnitzle,Daniel C. Brennan
出处
期刊:Transplantation
[Ovid Technologies (Wolters Kluwer)]
日期:2002-02-01
卷期号:73 (3): 473-475
被引量:114
标识
DOI:10.1097/00007890-200202150-00025
摘要
Background. The aim of this study was to demonstrate that 3-days of induction immunosuppression with thymoglobulin was as effective and safe as a 7-day course and reduced initial hospitalization after transplantation. Methods. This was a prospective, nonrandomized trial of 40 consecutive patients receiving thymoglobulin induction for 3 days and followed for 1 year. An historical group of 48 patients that received 7 days of thymoglobulin served as controls. Results. At 1 year, acute rejection (5 vs. 4%), graft survival (95vs. 98%) and patient survival were similar; a composite end point of freedom from death, rejection, or graft loss, the event-free graft survival, was similar as was the safety profile. In the 3-day group, lymphocyte depletion was more sustained and initial hospitalization was significantly shorter (6 vs. 8 days). Conclusion. Three-day induction with thymoglobulin is as effective and safe as seven days, decreases initial hospitalization and causes more sustained lymphocyte depletion.
科研通智能强力驱动
Strongly Powered by AbleSci AI